STOCK TITAN

[Form 4] Eliem Therapeutics, Inc Common Stock Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Hovnanian Enterprises, Inc. (HOV) – Form 4 insider transaction

Director Edward A. Kangas reported the sale of 5,500 shares of the company’s Class A common stock on 30 Jun 2025 at a weighted average price of $107.121 per share. Following the disposition, his direct holdings declined from 10,838 to 5,338 shares. No derivative security transactions were reported, and no 10b5-1 trading plan was indicated.

Hovnanian Enterprises, Inc. (HOV) – Transazione interna Form 4

Il direttore Edward A. Kangas ha comunicato la vendita di 5.500 azioni della classe A delle azioni ordinarie della società il 30 giugno 2025 ad un prezzo medio ponderato di 107,121 $ per azione. Dopo la vendita, la sua partecipazione diretta è diminuita da 10.838 a 5.338 azioni. Non sono state segnalate transazioni su strumenti derivati né è stato indicato alcun piano di trading 10b5-1.

Hovnanian Enterprises, Inc. (HOV) – Transacción interna Formulario 4

El director Edward A. Kangas reportó la venta de 5,500 acciones de la clase A de acciones comunes de la empresa el 30 de junio de 2025 a un precio promedio ponderado de $107.121 por acción. Tras la operación, sus participaciones directas disminuyeron de 10,838 a 5,338 acciones. No se reportaron transacciones con valores derivados ni se indicó ningún plan de trading 10b5-1.

호브나니언 엔터프라이즈, Inc. (HOV) – Form 4 내부자 거래

이사 에드워드 A. 캉가스2025년 6월 30일 회사의 클래스 A 보통주 5,500주를 주당 가중 평균 가격 $107.121에 매도했다고 보고했습니다. 처분 후 그의 직접 보유 주식은 10,838주에서 5,338주로 감소했습니다. 파생상품 거래는 보고되지 않았으며, 10b5-1 거래 계획도 없었습니다.

Hovnanian Enterprises, Inc. (HOV) – Transaction d’initié Formulaire 4

Le directeur Edward A. Kangas a déclaré la vente de 5 500 actions de la classe A des actions ordinaires de la société le 30 juin 2025 à un prix moyen pondéré de 107,121 $ par action. Suite à cette cession, ses participations directes ont diminué de 10 838 à 5 338 actions. Aucune transaction sur titres dérivés n’a été signalée, et aucun plan de trading 10b5-1 n’a été indiqué.

Hovnanian Enterprises, Inc. (HOV) – Insider-Transaktion Formular 4

Direktor Edward A. Kangas meldete den Verkauf von 5.500 Aktien der Klasse A Stammaktien des Unternehmens am 30. Juni 2025 zu einem gewichteten Durchschnittspreis von 107,121 $ pro Aktie. Nach der Veräußerung sank sein Direktbestand von 10.838 auf 5.338 Aktien. Es wurden keine Derivatgeschäfte gemeldet und kein 10b5-1 Handelsplan angegeben.

Positive
  • Director retains 5,338 shares, indicating continued equity interest in HOV despite the sale.
Negative
  • Insider disposition of 5,500 shares may signal reduced confidence or liquidity needs.

Insights

TL;DR: Small director sale; modestly negative sentiment, limited impact.

The disclosed sale reduces Mr. Kangas’s stake by roughly half, but absolute volume (5,500 shares) appears modest and no additional context on total share count or trading plan is given. Absence of derivative activity limits complexity. Insider sales can be viewed cautiously, yet the director retains 5,338 shares, signalling continuing alignment. With no earnings or strategic data attached, the filing carries minimal financial impact and is best interpreted as routine portfolio management.

Hovnanian Enterprises, Inc. (HOV) – Transazione interna Form 4

Il direttore Edward A. Kangas ha comunicato la vendita di 5.500 azioni della classe A delle azioni ordinarie della società il 30 giugno 2025 ad un prezzo medio ponderato di 107,121 $ per azione. Dopo la vendita, la sua partecipazione diretta è diminuita da 10.838 a 5.338 azioni. Non sono state segnalate transazioni su strumenti derivati né è stato indicato alcun piano di trading 10b5-1.

Hovnanian Enterprises, Inc. (HOV) – Transacción interna Formulario 4

El director Edward A. Kangas reportó la venta de 5,500 acciones de la clase A de acciones comunes de la empresa el 30 de junio de 2025 a un precio promedio ponderado de $107.121 por acción. Tras la operación, sus participaciones directas disminuyeron de 10,838 a 5,338 acciones. No se reportaron transacciones con valores derivados ni se indicó ningún plan de trading 10b5-1.

호브나니언 엔터프라이즈, Inc. (HOV) – Form 4 내부자 거래

이사 에드워드 A. 캉가스2025년 6월 30일 회사의 클래스 A 보통주 5,500주를 주당 가중 평균 가격 $107.121에 매도했다고 보고했습니다. 처분 후 그의 직접 보유 주식은 10,838주에서 5,338주로 감소했습니다. 파생상품 거래는 보고되지 않았으며, 10b5-1 거래 계획도 없었습니다.

Hovnanian Enterprises, Inc. (HOV) – Transaction d’initié Formulaire 4

Le directeur Edward A. Kangas a déclaré la vente de 5 500 actions de la classe A des actions ordinaires de la société le 30 juin 2025 à un prix moyen pondéré de 107,121 $ par action. Suite à cette cession, ses participations directes ont diminué de 10 838 à 5 338 actions. Aucune transaction sur titres dérivés n’a été signalée, et aucun plan de trading 10b5-1 n’a été indiqué.

Hovnanian Enterprises, Inc. (HOV) – Insider-Transaktion Formular 4

Direktor Edward A. Kangas meldete den Verkauf von 5.500 Aktien der Klasse A Stammaktien des Unternehmens am 30. Juni 2025 zu einem gewichteten Durchschnittspreis von 107,121 $ pro Aktie. Nach der Veräußerung sank sein Direktbestand von 10.838 auf 5.338 Aktien. Es wurden keine Derivatgeschäfte gemeldet und kein 10b5-1 Handelsplan angegeben.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Brennan Aoife

(Last) (First) (Middle)
C/O CLIMB BIO, INC.
20 WILLIAM STREET, SUITE 145

(Street)
WELLESLEY HILLS MA 02481

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Climb Bio, Inc. [ CLYM ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
President and CEO
3. Date of Earliest Transaction (Month/Day/Year)
06/27/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/27/2025 M 68,750 A (1) 68,750 D
Common Stock 06/30/2025 S(2) 20,618 D $1.22(3) 48,132 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units (4) 06/27/2025 M 68,750 (5) (5) Common Stock 68,750 $0 206,250 D
Explanation of Responses:
1. Each restricted stock unit ("RSU") converted into one share of the Issuer's Common Stock.
2. The sale reported on this Form 4 was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 30, 2024 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's RSUs.
3. The price reported is a weighted average price. These shares were sold in multiple transactions at prices within the range of $1.20 to $1.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
4. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
5. The RSUs were granted on June 27, 2024 (the "Grant Date") and are scheduled to vest over four years, with 25% of the shares vesting on each of the first four anniversaries of the Grant Date, subject to the Reporting Person's continued service.
Remarks:
Exhibit Index: 24.1 - Power of Attorney
/s/ Chandra Adams, as Attorney-in-Fact 07/01/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many HOV shares did Director Edward A. Kangas sell?

He sold 5,500 Class A common shares on 30 Jun 2025.

What price did the insider receive for the HOV shares?

The weighted average sale price was $107.121 per share.

How many HOV shares does the director still own after the transaction?

Mr. Kangas now directly owns 5,338 shares.

Were any derivative securities involved in the filing?

No, the Form 4 reports no derivative security transactions.

Does the Form 4 mention a Rule 10b5-1 trading plan?

The filing does not indicate that the sale was executed under a Rule 10b5-1 plan.
Eliem Therapeutics, Inc

NASDAQ:ELYM

ELYM Rankings

ELYM Latest News

ELYM Latest SEC Filings

ELYM Stock Data

342.68M
67.06M
10.38%
77.67%
1.72%
Biotechnology
Pharmaceutical Preparations
Link
United States
WILMINGTON